Literature DB >> 36081539

Fluoxetine and Molnupiravir: A Synergistic Combination for COVID-19 Treatment?

Yaser Pashaei1.   

Abstract

Entities:  

Year:  2022        PMID： 36081539      PMCID： PMC9445536          DOI： 10.1177/00185787211073465

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  9 in total

Review 1.  The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies.

Authors:  Vlad Dionisie; Gabriela Adriana Filip; Mihnea Costin Manea; Mirela Manea; Sorin Riga
Journal:  Inflammopharmacology       Date:  2020-11-08       Impact factor: 4.473

2.  Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.

Authors:  Sebastian Schloer; Linda Brunotte; Angeles Mecate-Zambrano; Shuyu Zheng; Jing Tang; Stephan Ludwig; Ursula Rescher
Journal:  Br J Pharmacol       Date:  2021-04-06       Impact factor: 8.739

Review 3.  Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Authors:  Yaser Pashaei
Journal:  J Clin Neurosci       Date:  2021-03-19       Impact factor: 1.961

4.  Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.

Authors:  Arthur Dechaumes; Magloire Pandoua Nekoua; Sandrine Belouzard; Famara Sane; Ilka Engelmann; Jean Dubuisson; Enagnon Kazali Alidjinou; Didier Hober
Journal:  Microorganisms       Date:  2021-02-09

5.  Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis.

Authors:  Guillaume Fond; Katlyn Nemani; Damien Etchecopar-Etchart; Anderson Loundou; Donald C Goff; Seung Won Lee; Christophe Lancon; Pascal Auquier; Karine Baumstarck; Pierre-Michel Llorca; Dong Keon Yon; Laurent Boyer
Journal:  JAMA Psychiatry       Date:  2021-11-01       Impact factor: 25.911

6.  Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.

Authors:  Sebastian Schloer; Linda Brunotte; Jonas Goretzko; Angeles Mecate-Zambrano; Nadia Korthals; Volker Gerke; Stephan Ludwig; Ursula Rescher
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

7.  Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.

Authors:  Justin Fortune Creeden; Ali Sajid Imami; Hunter M Eby; Cassidy Gillman; Kathryn N Becker; Jim Reigle; Elissar Andari; Zhixing K Pan; Sinead M O'Donovan; Robert E McCullumsmith; Cheryl B McCullumsmith
Journal:  Biomed Pharmacother       Date:  2021-02-25       Impact factor: 6.529
  9 in total
  2 in total

Review 1.  Potential of Azadirachta indica as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2.

Authors:  Frank Eric Tatsing Foka; Nanabi Manamela; Steven Maluta Mufamadi; Hazel Tumelo Mufhandu
Journal:  Biomed Res Int       Date:  2022-09-15       Impact factor: 3.246

2.  Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19.

Authors:  Nicolas Hoertel; Marina Sánchez-Rico; Johannes Kornhuber; Erich Gulbins; Angela M Reiersen; Eric J Lenze; Bradley A Fritz; Farid Jalali; Edward J Mills; Céline Cougoule; Alexander Carpinteiro; Christiane Mühle; Katrin Anne Becker; David R Boulware; Carlos Blanco; Jesús M Alvarado; Nathalie Strub-Wourgaft; Cédric Lemogne; Frédéric Limosin
Journal:  J Clin Med       Date:  2022-10-05       Impact factor: 4.964
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.